Precision epidemiology informing the drug development lifecycle.

Specialists in quantifying the current and future burden of non-communicable and rare genetic diseases.

Our data-driven epidemiology generates evidence to support strategic planning and portfolio management at each stage of the drug development process, helping to bring new therapies to patients faster.

Research and DevelopmentDetermining disease prevalence to establish development priorities.
 
Clinical TrialsDefining the most relevant patient groups to include in trials.
 
Market AccessGenerating disease burden studies to support HEOR teams with reimbursement and market access.
Market ExpansionDemonstrating the impact of new therapies on public health, and quantifying the impact of interventions.
Patient AdvocacyHighlighting unmet needs, and helping patient education campaigns raise awareness.

From molecule to market, our solutions can help.

 

Helping you at every stage

From informing early-stage R&D decisions through to market access and launch, view our solutions to find out how our data-driven epidemiology can support your product development, strategic planning and portfolio management.

Solutions

Why Us?

Deep expertise in disease epidemiology combined with entrepreneurial vision. Our work has been widely published and peer-reviewed by world-leading experts.

Why Us?

How do we do it?

We’ve spent over a decade developing our methodology to help you ask the right questions and make the best decisions.

Solutions

Whats our Track Record?

We’ve answered all kinds of questions for many different organisations, covering over 25 NCDs and rare genetic diseases in over 80 countries.

Track Record

WHO’S BEHIND IT?

Our experienced and multidisciplinary team brings together epidemiologists, geneticists, mathematicians, data scientists, researchers, and software engineers.

About Us

HealthLumen Blog

NEWS: HealthLumen launches AlleleAtlas, a tool for estimating the prevalence of rare genetic diseases 

HealthLumen has today announced the launch of AlleleAtlas, the genetic variant prevalence projection tool. The tool has been developed to bring a valuable resource to the rare disease community, including those engaged in rare disease research and therapeutics in the pharmaceutical, biotech and research spaces, and for patient advocacy organisations aiming to raise awareness.

Read

World Diabetes Day 2024: A holistic approach to tackling diabetes 

November 14th marks World Diabetes Day, a powerful opportunity to raise awareness of diabetes as a major global health issue. This year’s theme, “Breaking Barriers, Bridging Gaps”, calls for action to reduce diabetes risk factors and ensure equitable access to quality treatment worldwide [1].  The global diabetes crisis: A growing challenge  Diabetes currently impacts over […]

Read

HealthLumen modelling study for Nesta identifies the government interventions needed to halve obesity in the UK over five years

Study highlights which health policies are most likely to be effective in decreasing the prevalence of obesity, with fiscal policies expected to be particularly cost beneficial. This research has informed Nesta’s digital Blueprint tool – which provides data on the health, economic, and feasibility impacts of various obesity interventions – aligning with Nesta’s mission of halving obesity rates in the UK by 2030.

Read

Join HealthLumen at key upcoming rare disease conferences in Q4 2024 

HealthLumen are looking forward to discussing our work on the prevalence of rare diseases and engaging with colleagues dedicated to accelerating rare disease therapeutics at several upcoming conferences in the final quarter of this year.

Read